Gensight Biologics

This study tested the safety of a new gene therapy called GS010 for people with Leber Hereditary Optic Neuropathy (LHON), a genetic condition that causes sudden vision loss. Nineteen adults with a specific gene mutation received the treatment through an injection into the eye. Th…

This study followed 62 people with Leber Hereditary Optic Neuropathy (LHON) who received GS010 gene therapy in earlier trials. Researchers tracked eye safety and vision changes for up to 5 years after treatment. The goal was to see if the therapy remains safe and helps maintain v…

This study tested a gene therapy called GS010 in 98 people with Leber hereditary optic neuropathy (LHON), a genetic condition that causes sudden vision loss. Participants received injections into both eyes and were followed for up to 5 years. The goal was to see if the treatment …

This study tested a gene therapy called GS010 for people with Leber Hereditary Optic Neuropathy (LHON), a rare inherited eye disease that leads to vision loss. The trial included 37 participants who had vision loss for 6 to 12 months. They received a single injection of GS010 or …

This study tested a one-time gene therapy injection (GS010) in 39 people with Leber Hereditary Optic Neuropathy (LHON), a genetic condition that causes rapid vision loss. Participants had vision loss for 6 months or less. The goal was to see if the treatment could improve eyesigh…

This study looked at 44 people with Leber Hereditary Optic Neuropathy (LHON), a rare inherited eye disease that causes vision loss. Researchers reviewed medical records and asked participants about their vision and quality of life. The goal was to gather information on how the di…